OÊı·ÏÌÔÏÔÁ›· - Πανελλήνια Οφθαλμολογική Εταιρεία

OÊı·ÏÌÔÏÔÁ›·, 14, 2 (2002) 18328. Flanders M, Chin D, Boghen D. Botulinum toxin: preferredtreatment for hemifacial spasm. European Neurology33(4): 316-9, 1993.29. Olver JM. Botulinum toxin A treatment of overactivecorrugator supercilii in thyroid eye disease. BritishJournal of Ophthalmology 82(5): 528-33, 1998.30. Borodic GE. Botulinum A toxin for (expressionistic)ptosis overcorrection after frontalis sling. OphthalmicPlastic and Reconstructive Surgery 8(2): 137-42, 1992.31. Ebner R. Botulinum toxin type A in upper lid retractionof Graves’ ophthalmopathy. Journal of Clinical Neuro-Ophthalmology13(4): 258-61, 1993.32. Smet-Dieleman H, Van de Heyning PH, Tassignon MJ.Botulinum A toxin injection in patients with facialnerve palsy. Acta Oto-Rhino-Laryngologica Belgica47(3): 359-63, 1993.33. Clarke JR, Spalton DJ. Treatment of senile entropionwith botulinum toxin. British Journal of Ophthalmology72(5): 361-2, 1988.34. Carruthers JD. Ophthalmologic use of botulinum A exotoxin.Canadian Journal of Ophthalmology 20(4): 135-41, 1985.35. Steel DH, Hoh HB, Harrad RA, Collins CR. Botulinumtoxin for the temporary treatment of involutional lowerlid entropion: a clinical and morphological study.Eye 11(Pt 4): 472-5, 1997.36. Flynn JT, Bachynski B. Botulinum toxin therapy for strabismusand blepharospasm: Bascom Palmer Eye Instituteexperience. Transactions - New Orleans Academyof Ophthalmology 34: 73-88, 1986.37. Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J.Botulinum toxin treatment of synkinesia and hyperlacrimationafter facial palsy. Journal of Neurology,Neurosurgery & Psychiatry 65(1): 111-4, 1998.38. Hofmann RJ. Treatment of Frey’s syndrome (gustatorysweating) and ‘crocodile tears’ (gustatory epiphora)with purified botulinum toxin. Ophthalmic Plastic &Reconstructive Surgery 16(4): 289-91, 2000.39. Lowe NJ. Botulinum toxin type A for facial rejuvenation.United States and United Kingdom perspectives.Dermatologic Surgery: Official Publication For AmericanSociety For Dermatologic Surgery [Et Al.]24(11): 1216-8, 1998.40. West TB, Alster TS. Effect of botulinum toxin type A onmovement-associated rhytides following CO 2laser resurfacing.Dermatologic Surgery: Official PublicationFor American Society For Dermatologic Surgery [EtAl.] 25(4): 259-61, 1999.41. Annese V, Bassotti G, Coccia G, D_onofrio V, Gatto G,Repici A, et al. Comparison of two different formulationsof botulinum toxin A for the treatment of oesophagealachalasia. The Gismad Achalasia Study Group.Alimentary Pharmacology & Therapeutics 13(10):1347-50, 1999.42. Dunlop D, Pittar G, Dunlop C. Botulinum toxin inophthalmology. Australian & New Zealand Journal ofOphthalmology 16(1): 15-20, 1988.43. Ellis MF, Daniell M. An evaluation of the safety andefficacy of botulinum toxin type A (BOTOX) when u-sed to produce a protective ptosis. Clinical & ExperimentalOphthalmology 29(6): 394-9, 2001.44. Odergren T, Hjaltason H, Kaakkola S, Solders G, HankoJ, Fehling C, et al. A double blind, randomised, parallelgroup study to investigate the dose equivalence ofDysport and Botox in the treatment of cervical dystonia.Journal of Neurology, Neurosurgery, and Psychiatry64(1): 6-12, 1998.45. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respectivepotencies of Botox and Dysport: a double blind,randomised, crossover study in cervical dystonia. Journalof Neurology, Neurosurgery, and Psychiatry72(4): 459-62, 2002.46. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, MagalhaesM, Correia AP, et al. DYSBOT: a single-blind, randomizedparallel study to determine whether any differencescan be detected in the efficacy and tolerabilityof two formulations of botulinum toxin type A—Dysportand Botox—assuming a ratio of 4:1. MovementDisorders: Official Journal of the Movement DisorderSociety 12(6): 1013-8, 1997.47. Anderson RL, Gordy DD. The tarsal strip procedure. Archivesof Ophthalmology 97(11): 2192-6, 1979.48. Anderson Rl. The tarsal strip. Transactions New OrleansAcademy of Ophthalmology 30: 352-63, 1982.49. Patrinely JR, Whiting AS, Anderson RL. Local side effectsof botulinum toxin injections. Advances in Neurology49: 493-500, 1988.50. Biglan AW, Gonnering R, Lockhart LB, Rabin B, FuersteFH. Absence of antibody production in patients treatedwith botulinum A toxin. American Journal ofOphthalmology 101(2): 232-5, 1986.51. Lingua RW. Sequelae of botulinum toxin injection. AmericanJournal of Ophthalmology 100(2): 305-7, 1985.52. Balkan RJ, Poole T. A five-year analysis of botulinumtoxin type A injections: some unusual features. Annalsof Ophthalmology 23(9): 326-33, 1991.53. Harris CP, Alderson K, Nebeker J, Holds JB, AndersonRL. Histologic features of human orbicularis oculi treatedwith botulinum A toxin. Archives of Ophthalmology109(3): 393-5, 1991.54. Price J, O’Day J. Efficacy and side effects of botulinumtoxin treatment for blepharospasm and hemifacialspasm. Australian and New Zealand Journal of Ophthalmology22(4): 255-60, 1994.55. Corridan P, Nightingale S, Mashoudi N, Williams AC. A-cute angle-closure glaucoma following botulinum toxininjection for blepharospasm [see comments]. BritishJournal of Ophthalmology 74(5): 309-10, 1990.56. Borodic GE, Ferrante R. Effects of repeated botulinumtoxin injections on orbicularis oculi muscle. Journal ofClinical Neuro-Ophthalmology 12(2): 121-7, 1992.57. Schechter RJ. Ptosis with contralateral lid retraction dueto excessive innervation of the levator palpebrae superiorus.Annals of Ophthalmology 10(10): 1324-8, 1978.